摘要
目的探讨IMOP方案治疗非霍奇金氏淋巴瘤的疗效和毒性.方法对我科1996年3月～1999年3月共收治的经病理确诊为非霍奇金氏淋巴瘤的初治患者81例的临床资料进行回顾性分析.41例患者予IMOP方案治疗,40例患者予CHOP方案治疗.IMOP治疗组:异环磷酰胺(IFO)1.2g/m2,静脉滴注,第1～5天.米托蒽醌(MIT)10mg/m2,静脉注射,第1天.长春新碱(VCR)1.4 mg/m2,静脉注射,第1天.强的松(Pred)40mg/m2,口服,第1～5天.CHOP治疗组:环磷酰胺(CTX)750 mg/m2,静脉滴注,第1天.阿霉素(ADM)40mg/m2,静脉注射,第1天.长春新碱(VCR)1.4 mg/m2,静脉注射,第1、8天,强的松(Pred)40mg/m2,口服,第1～5天.两组患者均每3周重复,共4～6个周期.结果两组患者特征具有可比性(P＞0.05),IMOP治疗组41例的完全缓解率为70%(29/41),总有效率约为87.8%(36/41),5年生存率约为58.82%,CHOP治疗组完全缓解率为52.5%(21/40),总有效率约为65%(26/40),5年生存率约为28.77%,两者具有显著差异(P＜0.05).两组治疗的主要毒副作用为骨髓抑制,但两者无显著差异(P＞0.05).结论研究结果表明IMOP方案是治疗非霍奇金氏淋巴瘤的有效方案.
Objective: To evaluate the efficacy and toxicity of IMOP regimen to treat non-Hodgkin′s lymphoma. Methods: From march 1996 to march 1999, 81 cases with histologically and immunohistochemically proven non-Hodgkin′s lymphoma were analyzed retrospectively. They were divided into two groups: GroupⅠ, 41 cases were treated by IMOP regimen, it consisted of IFO 1.2 g/m2(i.v.drop.day1~5), MIT 10 mg/m2(i.v.day1), VCR1.4 mg/m2 (i.v.day1), Pred 40 mg/m2 (po.day1~5); Group Ⅱ, 40 cases were treated by CHOP regimen. it consisted of 750 mg/m2 (iv.drop.day1), ADM 40 mg/m2 (iv.day1), VCR 1.4 mg/m2 (iv.day1, 8), Pred 40 mg/m2(po.day1~5), Both groups were repeated every 3 weeks. Results: Patients in both group were well matched with baseline disease characteristics(P>0.05). 81 cases with non-Hodgkin′s lymphoma entered into this study, 41 patients received IMOP regimen, the complete remission rate was 70%(29/41), the overall response rate was 87.8%(36/41)and the 5 year survived rate was 58.82%, 40 patients received CHOP regimen, the complete remission rate was 52.5%(21/40), the overall response rate was 65% (26/40) and the 5 year survive rate was 28.77%, There was a significant difference in the complete remission rate between the two groups (P<0.05). The toxicity were myelosuppression, but there wasn′t a significant difference (P>0.05). Conclusions: The results of this study demonstrate that IMOP regimen may be more effective than CHOP regimen. So this regimen can be considered as a effective regimen for non-Hodgkin′s lymphoma.
出处
《中国医学工程》
2004年第5期86-88,共3页
China Medical Engineering
